13 November 2013

ASX ANNOUNCEMENT

AMERICAN MEDICAL ASSOCIATION (AMA) ACCEPTS RECOMMENDATION FOR CATEGORY I CPT® CODE FOR BIOIMPEDANCE LYMPHOEDEMA ASSESSMENT

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“the Company”), announced today that the AMA has posted their CPT Editorial Summary of Panel Actions from the October 10-12, 2013 CPT Panel Meeting. The CPT Panel made a recommendation to accept the addition of Category I CPT code 937XX2 and delete Category III code 0239T for bioimpedance spectroscopy lymphedema assessment for extracellular fluid. Category I CPT codes are reserved for those procedures that have demonstrated clinical efficacy, widespread use and have U.S. Food and Drug Administration (FDA) clearance.

Current Procedural Terminology (CPT) is a listing of descriptive terms and identifying codes for reporting medical services and procedures. The purpose of CPT is to provide a uniform language that accurately describes medical, surgical, and diagnostic services, and thereby serves as an effective means for reliable nationwide communication among physicians and other healthcare providers, patients, and third parties in the United States. CPT is the most widely accepted medical nomenclature used to report medical procedures and services under public and private health insurance programs.

Please note that this is a result of the most recent CPT Panel meeting. Future CPT Panel actions may impact this information. New and revised code descriptions may be further refined prior to publication each year. For this reason, code numbers are not assigned, nor exact wording finalized, until just prior to publication of the annual CPT code set. Decisions made from this Panel meeting become effective 01 January 2015.

For further information contact: Richard Carreon, ImpediMed CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

CPT® is registered trademark of the American Medical Association.

About ImpediMed
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit www.impedimed.com.au